Discover our studies and give a look to inclusion criteria

S-1 Real-World is a prospective, observational, multicenter real-world study on the use of S-1 for…

PRODIGE 86 (FFCD 2103) – FOLFIRINOX SBA is an European study in which GONO is participating as part…

Fruit is an observational, multicenter, retrospective and prospective Real-World Study on the use…

Colosoto is the first European study in which GONO is participating as part of the international…

Pancreatic cancer is a deadly neoplasm with more than 95% of patients affected dying of their…

GI-PREDICT is an observational platform study in which predictive biomarkers of…

LONGEVITY is an observational retrospective study enrolling patients with gastric (GC) or GEJ…

FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab is, currently,…

Based on the results of the phase III BEACON study, combination of encorafenib and cetuximab is…

TRINITY is a multicentre, randomized, open-label, interventional phase II study aimed at…

UNICORN is a Phase II, multicentre, window-of-opportunity umbrella platform trial aimed at…

PURITY is a no-profit, multicentre, randomized adaptive phase II/III trial aimed at improving…

The Merkel cell carcinoma (MCC) is an extremely rare cutaneous epithelial malignancy with highly…

Stage III colorectal cancer (CRC) patients are currently treated with three- or sixmonths of…

INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the…

The association of doublet chemotherapy (FOLFOX and FOLFIRI) and anti-EGFR moAbs (panitumumab or…

The standard treatment for locally advanced rectal cancer (LARC) patients is based on neoadjuvant…

5-Fluorouracil or capecitabine plus bevacizumab are recommended by major international guidelines…